EKSO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EKSO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Ekso Bionics Holdings's Cost of Goods Sold for the three months ended in Sep. 2024 was $1.92 Mil. Ekso Bionics Holdings's Average Total Inventories for the quarter that ended in Sep. 2024 was $5.00 Mil. Ekso Bionics Holdings's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.38.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ekso Bionics Holdings's Days Inventory for the three months ended in Sep. 2024 was 237.75.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ekso Bionics Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 1.21.
The historical data trend for Ekso Bionics Holdings's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ekso Bionics Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Inventory Turnover | Get a 7-Day Free Trial | 2.44 | 1.71 | 2.13 | 1.80 | 1.80 |
Ekso Bionics Holdings Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Inventory Turnover | Get a 7-Day Free Trial | 0.39 | 0.47 | 0.36 | 0.46 | 0.38 |
Ekso Bionics Holdings's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 9.2 | / ( | (5.187 | + | 5.05) | / | 2 ) |
= | 9.2 | / | 5.1185 | ||||
= | 1.80 |
Ekso Bionics Holdings's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as
Inventory Turnover (Q: Sep. 2024 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Sep. 2024 ) | / ( | (Total Inventories (Q: Jun. 2024 ) | + | Total Inventories (Q: Sep. 2024 )) | / | count ) |
= | 1.92 | / ( | (4.974 | + | 5.031) | / | 2 ) |
= | 1.92 | / | 5.0025 | ||||
= | 0.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ekso Bionics Holdings (NAS:EKSO) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ekso Bionics Holdings's Days Inventory for the three months ended in Sep. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2024 ) | / | Cost of Goods Sold (Q: Sep. 2024 ) | * | Days in Period |
= | 5.0025 | / | 1.92 | * | 365 / 4 | |
= | 237.75 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ekso Bionics Holdings's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | 5.0025 | / | 4.129 | |
= | 1.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Ekso Bionics Holdings's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Lathan Corinna | director | 140 KENDRICK STREET, NEEDHAM MA 02494 |
Jerome Wong | officer: Interim CFO | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Scott G. Davis | officer: President & COO | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Steven Sherman | director | |
Jason C Jones | officer: VP of Product Development | EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
John Glenn | officer: Chief Financial Officer | 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577 |
William R Shaw | officer: See Remarks | 1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804 |
Rhonda A. Wallen | director | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Mary Ann Cloyd | director | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Combest Development (hong Kong) Ltd | 10 percent owner | ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077 |
Jack Peurach | director, officer: Chief Executive Officer | 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Thomas A Schreck | director | 10240 BUBB RD, CUPERTINO CA 95014 |
Puissance Capital Management (gp) Llc | 10 percent owner | 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Theodore T Wang | director, 10 percent owner | C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Christian Babini | officer: VP of Sales, Americas | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804 |
From GuruFocus
By Marketwired • 10-28-2024
By Marketwired • 07-29-2024
By GuruFocus News • 11-15-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 04-22-2024
By GuruFocus Research • 04-30-2024
By Marketwired • 07-22-2024
By Marketwired • 06-17-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.